Clinical Trial

A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic Diseases

Name: A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic Diseases — clinical trial record (NCT07712939)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary clinical activity of CND319 in healthy adult participants and patients with rheumatic diseases.

Protocol Amendment History 1 change

critical Recruitment opened 2026-07-23

Trial Details

NCT Number	NCT07712939
Lead Sponsor	Candid Therapeutics
Conditions	Healthy Participants Study, Rheumatoid Arthritis, Sjogren's Syndrome
Enrollment	105 participants
Start Date	2026-07-20
Primary Completion	2028-03-31 (estimated)
Study Completion	2028-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-22